Allogene Therapeutics (ALLO) Competitors

$1.94 -0.06 (-3.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.97 +0.03 (+1.55%)

As of 07:45 PM Eastern

ALLO vs. ADPT, NBTX, BHC, OCUL, and ZLAB

Should you buy Allogene Therapeutics stock or one of its competitors? MarketBeat compares Allogene Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Allogene Therapeutics include Adaptive Biotechnologies (ADPT), Nanobiotix (NBTX), Bausch Health Cos (BHC), Ocular Therapeutix (OCUL), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical products" industry.

How does Allogene Therapeutics compare to Adaptive Biotechnologies?

Adaptive Biotechnologies (NASDAQ:ADPT) and Allogene Therapeutics (NASDAQ:ALLO) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

Adaptive Biotechnologies has higher revenue and earnings than Allogene Therapeutics. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$276.98M	7.34	-$59.50M	-$0.33	N/A
Allogene Therapeutics	$20K	23,747.54	-$190.89M	-$0.77	N/A

Adaptive Biotechnologies currently has a consensus target price of $19.57, suggesting a potential upside of 53.98%. Allogene Therapeutics has a consensus target price of $8.52, suggesting a potential upside of 339.29%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Allogene Therapeutics is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

99.2% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 5.7% of Adaptive Biotechnologies shares are owned by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Allogene Therapeutics had 5 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 11 mentions for Allogene Therapeutics and 6 mentions for Adaptive Biotechnologies. Allogene Therapeutics' average media sentiment score of 0.48 beat Adaptive Biotechnologies' score of 0.41 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Allogene Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Allogene Therapeutics has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -16.82%. Adaptive Biotechnologies' return on equity of -40.06% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%
Allogene Therapeutics	N/A	-56.45%	-40.36%

Adaptive Biotechnologies has a beta of 2.16, suggesting that its stock price is 116% more volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market.

Summary

Allogene Therapeutics beats Adaptive Biotechnologies on 10 of the 17 factors compared between the two stocks.

How does Allogene Therapeutics compare to Nanobiotix?

Allogene Therapeutics (NASDAQ:ALLO) and Nanobiotix (NASDAQ:NBTX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Allogene Therapeutics has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market.

Nanobiotix has higher revenue and earnings than Allogene Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	23,747.54	-$190.89M	-$0.77	N/A
Nanobiotix	$36.87M	65.11	-$27.11M	N/A	N/A

83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 38.8% of Nanobiotix shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by company insiders. Comparatively, 3.5% of Nanobiotix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Nanobiotix's return on equity of 0.00% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-56.45%	-40.36%
Nanobiotix	N/A	N/A	N/A

Allogene Therapeutics currently has a consensus target price of $8.52, suggesting a potential upside of 339.29%. Nanobiotix has a consensus target price of $26.67, suggesting a potential downside of 46.11%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Allogene Therapeutics is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Allogene Therapeutics had 10 more articles in the media than Nanobiotix. MarketBeat recorded 11 mentions for Allogene Therapeutics and 1 mentions for Nanobiotix. Allogene Therapeutics' average media sentiment score of 0.48 beat Nanobiotix's score of 0.42 indicating that Allogene Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nanobiotix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Allogene Therapeutics beats Nanobiotix on 9 of the 14 factors compared between the two stocks.

How does Allogene Therapeutics compare to Bausch Health Cos?

Allogene Therapeutics (NASDAQ:ALLO) and Bausch Health Cos (NYSE:BHC) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

83.6% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are owned by institutional investors. 13.2% of Allogene Therapeutics shares are owned by company insiders. Comparatively, 20.7% of Bausch Health Cos shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Bausch Health Cos has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	23,747.54	-$190.89M	-$0.77	N/A
Bausch Health Cos	$10.27B	0.19	$157M	-$3.24	N/A

Allogene Therapeutics presently has a consensus price target of $8.52, indicating a potential upside of 339.29%. Bausch Health Cos has a consensus price target of $8.00, indicating a potential upside of 49.39%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Allogene Therapeutics is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Allogene Therapeutics has a net margin of 0.00% compared to Bausch Health Cos' net margin of -11.47%. Allogene Therapeutics' return on equity of -56.45% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-56.45%	-40.36%
Bausch Health Cos	-11.47%	-2,922.77%	5.63%

In the previous week, Allogene Therapeutics had 5 more articles in the media than Bausch Health Cos. MarketBeat recorded 11 mentions for Allogene Therapeutics and 6 mentions for Bausch Health Cos. Allogene Therapeutics' average media sentiment score of 0.48 beat Bausch Health Cos' score of 0.00 indicating that Allogene Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bausch Health Cos	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Allogene Therapeutics has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market.

Summary

Allogene Therapeutics beats Bausch Health Cos on 12 of the 17 factors compared between the two stocks.

How does Allogene Therapeutics compare to Ocular Therapeutix?

Allogene Therapeutics (NASDAQ:ALLO) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

Allogene Therapeutics presently has a consensus target price of $8.52, suggesting a potential upside of 339.29%. Ocular Therapeutix has a consensus target price of $23.78, suggesting a potential upside of 183.74%. Given Allogene Therapeutics' higher possible upside, analysts plainly believe Allogene Therapeutics is more favorable than Ocular Therapeutix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Allogene Therapeutics has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

Allogene Therapeutics has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -558.24%. Allogene Therapeutics' return on equity of -56.45% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-56.45%	-40.36%
Ocular Therapeutix	-558.24%	-64.28%	-48.15%

Allogene Therapeutics has higher earnings, but lower revenue than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	23,747.54	-$190.89M	-$0.77	N/A
Ocular Therapeutix	$51.95M	35.32	-$265.94M	-$1.46	N/A

In the previous week, Allogene Therapeutics had 7 more articles in the media than Ocular Therapeutix. MarketBeat recorded 11 mentions for Allogene Therapeutics and 4 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 0.49 beat Allogene Therapeutics' score of 0.48 indicating that Ocular Therapeutix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ocular Therapeutix	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by insiders. Comparatively, 2.3% of Ocular Therapeutix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Allogene Therapeutics beats Ocular Therapeutix on 12 of the 17 factors compared between the two stocks.

How does Allogene Therapeutics compare to Zai Lab?

Allogene Therapeutics (NASDAQ:ALLO) and Zai Lab (NASDAQ:ZLAB) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

In the previous week, Allogene Therapeutics had 5 more articles in the media than Zai Lab. MarketBeat recorded 11 mentions for Allogene Therapeutics and 6 mentions for Zai Lab. Allogene Therapeutics' average media sentiment score of 0.48 beat Zai Lab's score of 0.18 indicating that Allogene Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zai Lab	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Allogene Therapeutics has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market. Comparatively, Zai Lab has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market.

83.6% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 41.7% of Zai Lab shares are owned by institutional investors. 13.2% of Allogene Therapeutics shares are owned by company insiders. Comparatively, 4.9% of Zai Lab shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Allogene Therapeutics currently has a consensus target price of $8.52, suggesting a potential upside of 339.29%. Zai Lab has a consensus target price of $45.83, suggesting a potential upside of 143.02%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Allogene Therapeutics is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Zai Lab	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.63

Zai Lab has higher revenue and earnings than Allogene Therapeutics. Zai Lab is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	23,747.54	-$190.89M	-$0.77	N/A
Zai Lab	$460.16M	4.65	-$175.54M	-$1.62	N/A

Allogene Therapeutics has a net margin of 0.00% compared to Zai Lab's net margin of -39.29%. Zai Lab's return on equity of -24.32% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-56.45%	-40.36%
Zai Lab	-39.29%	-24.32%	-15.52%

Summary

Allogene Therapeutics beats Zai Lab on 11 of the 16 factors compared between the two stocks.

Get Allogene Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALLO vs. The Competition

Export

Metric	Allogene Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$474.95M	$3.26B	$6.23B	$12.22B
Dividend Yield	N/A	2.34%	2.80%	5.30%
P/E Ratio	-2.52	18.45	20.66	25.25
Price / Sales	23,747.54	278.55	546.74	70.60
Price / Cash	N/A	55.27	27.48	37.27
Price / Book	1.49	6.57	9.67	6.63
Net Income	-$190.89M	$24.35M	$3.56B	$335.32M
7 Day Performance	-14.91%	-3.17%	-1.91%	-1.83%
1 Month Performance	-18.83%	-3.55%	-2.65%	-1.16%
1 Year Performance	74.77%	56.89%	31.17%	28.31%

Allogene Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALLO Allogene Therapeutics	2.8666 of 5 stars	$1.94 -3.0%	$8.52 +339.3%	+80.2%	$474.95M	$20K	N/A	310	Earnings Report
ADPT Adaptive Biotechnologies	3.5159 of 5 stars	$13.54 -2.0%	$20.00 +47.7%	+41.8%	$2.21B	$276.98M	N/A	790
NBTX Nanobiotix	1.5307 of 5 stars	$53.55 +17.7%	$26.67 -50.2%	+1,225.6%	$2.21B	$36.87M	N/A	100	Analyst Forecast High Trading Volume
BHC Bausch Health Cos	2.0519 of 5 stars	$5.36 -6.9%	$8.00 +49.4%	+16.0%	$2.15B	$10.27B	N/A	20,300
OCUL Ocular Therapeutix	3.5271 of 5 stars	$9.28 -3.8%	$23.78 +156.2%	+26.9%	$2.11B	$51.95M	N/A	230

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALLO) was last updated on 5/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Allogene Therapeutics (ALLO) Competitors

ALLO vs. ADPT, NBTX, BHC, OCUL, and ZLAB

How does Allogene Therapeutics compare to Adaptive Biotechnologies?

Summary

How does Allogene Therapeutics compare to Nanobiotix?

Summary

How does Allogene Therapeutics compare to Bausch Health Cos?

Summary

How does Allogene Therapeutics compare to Ocular Therapeutix?

Summary

How does Allogene Therapeutics compare to Zai Lab?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLO vs. The Competition

Allogene Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Allogene Therapeutics (ALLO) Competitors

ALLO vs. ADPT, NBTX, BHC, OCUL, and ZLAB

How does Allogene Therapeutics compare to Adaptive Biotechnologies?

Which has better valuation and earnings, ADPT or ALLO?

Do analysts recommend ADPT or ALLO?

Do insiders and institutionals hold more shares of ADPT or ALLO?

Does the media favor ADPT or ALLO?

Is ADPT or ALLO more profitable?

Which has more volatility & risk, ADPT or ALLO?

Summary

How does Allogene Therapeutics compare to Nanobiotix?

Which has more risk & volatility, ALLO or NBTX?

Which has better earnings & valuation, ALLO or NBTX?

Do insiders and institutionals have more ownership in ALLO or NBTX?

Is ALLO or NBTX more profitable?

Do analysts prefer ALLO or NBTX?

Does the media prefer ALLO or NBTX?

Summary

How does Allogene Therapeutics compare to Bausch Health Cos?

Do insiders and institutionals believe in ALLO or BHC?

Which has better valuation and earnings, ALLO or BHC?

Do analysts recommend ALLO or BHC?

Is ALLO or BHC more profitable?

Does the media refer more to ALLO or BHC?

Which has more volatility & risk, ALLO or BHC?

Summary

How does Allogene Therapeutics compare to Ocular Therapeutix?

Do analysts prefer ALLO or OCUL?

Which has more risk and volatility, ALLO or OCUL?

Is ALLO or OCUL more profitable?

Which has higher earnings and valuation, ALLO or OCUL?

Does the media refer more to ALLO or OCUL?

Do insiders & institutionals hold more shares of ALLO or OCUL?

Summary

How does Allogene Therapeutics compare to Zai Lab?

Does the media prefer ALLO or ZLAB?

Which has more volatility & risk, ALLO or ZLAB?

Do insiders & institutionals have more ownership in ALLO or ZLAB?

Do analysts rate ALLO or ZLAB?

Which has better earnings and valuation, ALLO or ZLAB?

Is ALLO or ZLAB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLO vs. The Competition

Allogene Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools